QQ客服 官方微博 反馈留言

	A phase I dose expansion study of epitinib to evaluate efficacy and safety in EGFR mutation positive (EGFRM+) NSCLC patients with brain metastasis
	Zhou Q., Gan B., Hong Q., Wang M., Liu X., Yuan L., Hua Y., Ren H., Su W., Wu Y.L.
刊名	Journal of Thoracic Oncology
	2017
卷号	12
ISSN号	1556-1380
URL标识	查看原文
语种	英语
内容类型	期刊论文
URI标识	http://www.corc.org.cn/handle/1471x/3610965
专题	复旦大学上海医学院
推荐引用方式 GB/T 7714	Zhou Q., Gan B., Hong Q., Wang M., Liu X., Yuan L., Hua Y., Ren H., Su W., Wu Y.L.. A phase I dose expansion study of epitinib to evaluate efficacy and safety in EGFR mutation positive (EGFRM+) NSCLC patients with brain metastasis[J]. Journal of Thoracic Oncology,2017,12.
APA	Zhou Q., Gan B., Hong Q., Wang M., Liu X., Yuan L., Hua Y., Ren H., Su W., Wu Y.L..(2017).A phase I dose expansion study of epitinib to evaluate efficacy and safety in EGFR mutation positive (EGFRM+) NSCLC patients with brain metastasis.Journal of Thoracic Oncology,12.
MLA	Zhou Q., Gan B., Hong Q., Wang M., Liu X., Yuan L., Hua Y., Ren H., Su W., Wu Y.L.."A phase I dose expansion study of epitinib to evaluate efficacy and safety in EGFR mutation positive (EGFRM+) NSCLC patients with brain metastasis".Journal of Thoracic Oncology 12(2017).

个性服务

查看访问统计

相关权益政策

暂无数据

收藏/分享

除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。